Takeda Expects FY23 Revenue of JPY3.98T (Prior JPY3.84T), Core EPS of JPY447 (Prior JPY434)
Portfolio Pulse from Benzinga Newsdesk
Takeda Pharmaceutical Company Limited (TAK) has revised its full-year FY2023 reported and core forecasts, based on its first half results and expected foreign exchange rates during the second half of FY2023. The company now expects FY23 revenue of JPY3.98T, up from the prior forecast of JPY3.84T, and a core EPS of JPY447, up from the prior JPY434. However, the company expects a decline in reported operating profit, reported net profit, and core EPS.
October 26, 2023 | 7:39 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Takeda has revised its FY23 forecasts, expecting higher revenue and core EPS, but lower operating profit, net profit, and core EPS. This mixed forecast could lead to uncertainty among investors.
Takeda's revised forecast presents a mixed picture. While the company expects higher revenue and core EPS, it also anticipates lower operating profit, net profit, and core EPS. This could lead to uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100